Nature Reviews Drug Discovery contents August 2011 Volume 10 Number 8 pp 557-637

Advertisement
Roche's Cellavista Imaging - Be the Master of your Cells Automated high-throughput imaging using bright field and fluorescence for an unlimited number of cellular assays, examining monoclonality control, cytotoxicity testing, and cell cycle analysis. https://www.roche-applied-science.com/sis/innovatis For life science research only. Not for use in diagnostic procedures.
TABLE OF CONTENTS
August 2011 Volume 10 Number 8		Advertisement
Impact Factor 28.712 * Subscribe to Nature Reviews Drug Discovery Recommend to your library	In this issue Comment News and Analysis Research Highlights Analysis Reviews Also this month Poster and video: The 50–year quest to replace warfarin Featured article: Cancer immunotherapy — revisited W. Joost Lesterhuis, John B. A. G. Haanen & Cornelis J. A. Punt	Lead Discovery / Lead Optimization / Pre-Clinical Development "Our experience in successfully developing projects both internally and in collaboration with customers stands as a testament to our ability to provide high level project management, well developed and tested solutions, and added-value to our customers," Dr. Bruce Sargent, AMRI Senior Vice President, Drug Discovery.
Advertisement
BioPharma Dealmakers Science, strategy & innovation Recent content exclusively made freely available to you from Nature Biotechnology, Nature Reviews Drug Discovery and Nature Medicine Produced with support from TVG Sign up to receive this new bi-weekly newsletter today.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Immunology presents a webcast series Current Controversies: HIV Vaccines August 10th 2011 12pm EST / 9am PST / 6pm CET Please join us for a lively discussion on the search for an effective HIV vaccine, followed by a live question and answer session. Speakers: Dr. Ronald Desrosiers and Dr. Louis Picker Register for FREE. Sponsored by:
In this issue p557 | doi:10.1038/nrd3513 Full Text
Comment: John L. LaMattina p559 | doi:10.1038/nrd3514 Abstract | Full Text | PDF | Supplementary information The impact of mergers on pharmaceutical R&D
NEWS AND ANALYSIS		Top
Partnering between pharma peers on the rise Asher Mullard p561 | doi:10.1038/nrd3526 Pharmaceutical–academia deals have been stealing headlines this year, but more complex models of pharma–pharma collaboration are increasingly being seen as potential solutions to industry's most intractable challenges. PDF
PI3K pathway inhibitors approach junction David Holmes p563 | doi:10.1038/nrd3527 The PI3K–AKT–mTOR pathway has long been an attractive oncology target. But with top-line results from the most advanced AKT inhibitor due soon, many questions remain over which targets to hit and how to combine agents. PDF
NEWS IN BRIEF A bumper year for the FDA | Regulating in harmony | Antibodies in space p565 | doi:10.1038/nrd3528 PDF
BIOBUSINESS BRIEFS Deal watch: Boosting TRegs to target autoimmune disease p566 | doi:10.1038/nrd3517 PDF
Trial watch: Nalmefene reduces alcohol use in phase III trial p566 | doi:10.1038/nrd3518 PDF
Market watch: Pricing strategies for emerging markets Neil Lineberry, Eric Snyder & Seema Gunda p567 | doi:10.1038/nrd3519 PDF
PATENT WATCH MedImmune's phage display patents invalidated | Clear and convincing evidence still needed to invalidate patents | European Patent Office overturns Nexium patent | TRPM8 channel modulators p568 | doi:10.1038/nrd3529 PDF
AN AUDIENCE WITH Robert Dworkin p570 | doi:10.1038/nrd3530 Robert Dworkin, Director of ACTION, discusses the public–private partnership's plans to revamp clinical trial design for pain drugs. PDF
FROM THE ANALYST'S COUCH The Parkinson's disease market Trung Huynh p571 | doi:10.1038/nrd3515 PDF
FRESH FROM THE PIPELINE Abiraterone acetate Christopher J. Logothetis, Eleni Efstathiou, Fil Manuguid & Peter Kirkpatrick p573 | doi:10.1038/nrd3516 PDF
RESEARCH HIGHLIGHTS Top Cancer: Vaccine cure for prostate cancer? p575 | doi:10.1038/nrd3524 PDF Neurodegenerative disorders: Restoring the balance p576 | doi:10.1038/nrd3521 PDF Obesity and diabetes: Lipid boosts muscle and shrinks fat p576 | doi:10.1038/nrd3522 PDF Mood disorders: Targeting protein synthesis for fast antidepressant action p577 | doi:10.1038/nrd3520 PDF Cardiovascular disorders: Resolving blood clots p578 | doi:10.1038/nrd3523 PDF Drug Discovery JOBS of the week Director of Surgical Pathology University of Wisconsin-Madison Madison, Wisconsin De Montfort University: Postgraduate and Research Opportunities De Montfort University Leicester, LE1 9BH, England Faculty Position Lehigh University Bethlehem, PA Senior Scientist SAIC-Frederick, Inc. Frederick, MD Technology Platform Managers Regional Centre for Biotechnology Gurgaon, India More Science jobs from Drug Discovery EVENT ADME, PK/TK, and Drug Metabolism in Drug Discovery and Development 14.-16.09.11 PA, US More science events from
ANALYSIS		Top
Trends in the exploitation of novel drug targets Mathias Rask-Andersen, Markus Sällman Almén & Helgi B. Schiöth p579 | doi:10.1038/nrd3478 Schiöth and colleagues examine the drugs approved by the US Food and Drug Administration over the past 30 years and analyse the interactions of these drugs with therapeutic targets encoded by the human genome, identifying 435 effect-mediating drug targets. They also analyse trends in the introduction of drugs that modulate previously unexploited targets, and discuss the network pharmacology of the drugs in the data set. Abstract | Full Text | PDF | Supplementary information
Advertisement
Whole-Genome & Exome Functional Interpretation Solutions KnomeDISCOVERY quickly delivers a shortlist of suspect variants, genes, and networks-bringing the power of comparative whole genome interpretation to your research. Our project-driven curation integrates diverse streams of public and proprietary reference data to glean insights from whole genomes in discovery studies and clinical trials. Now $4,998 per genome (min 10), including sequencing and functional/comparative interpretation. Click here for information: www.knome.com
REVIEWS		Top
Cancer immunotherapy – revisited W. Joost Lesterhuis, John B. A. G. Haanen & Cornelis J. A. Punt p591 | doi:10.1038/nrd3500 Although our insight into antitumour immune responses has increased substantially in the past few decades, the development of immunotherapy for cancer has been hampered by challenges including the identification of optimal treatment strategies and methods to evaluate them. However, as Punt and colleagues discuss, the recent positive results of clinical trials with novel immunological drugs, as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy, may herald a new era for cancer immunotherapy. Abstract | Full Text | PDF
Transient receptor potential channels as therapeutic targets Magdalene M. Moran, Michael Allen McAlexander, Tamás Bíró & Arpad Szallasi p601 | doi:10.1038/nrd3456 Transient receptor potential (TRP) channels are a diverse family of cation channels. Here, the authors discuss recent developments in this area, highlight recent developments and setbacks in the field of pain research and analyse TRP channels as targets for skin, pulmonary and urological disorders. Abstract | Full Text | PDF | Supplementary information
Targeting RNA to treat neuromuscular disease Francesco Muntoni & Matthew J. A. Wood p621 | doi:10.1038/nrd3459 The development of effective therapies for neuromuscular disorders is hampered by considerable challenges, including the abundance of skeletal muscle within the body and the multisystemic nature of many of these diseases. Here, Muntoni and Wood review recent advances in the development of novel therapies that target RNA, which are exemplified by three disorders: Duchenne muscular dystrophy, myotonic dystrophy and spinal muscular atrophy. Abstract | Full Text | PDF
Advertisement
UCSD Clinical and Translational Research Institute and Nature Medicine present: Vascular Disease 2011: From bench to bedside October 13-15, 2011 • La Jolla, CA, USA This meeting will explore innovative approaches to bridge laboratory investigation and clinical research in disorders affecting the vasculature, including cancer, inflammatory disease and cardiovascular disease. For more information and to register visit: www.nature.com/natureconferences/b2b2011?WT.mc_id=NC1105TK010
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.